(E/Z)-SOXAZOL-3-YL(2-((2,3,5-TRIMETHYLPHENOXY)METHYL)PHENYL)METHANONE O-METHYL OXIME


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	NTTJNFZXIQREIL-UHFFFAOYSA-N
Smiles	CO\N=C(/c1ccon1)\c2ccccc2COc3cc(C)cc(C)c3C
InChI	InChI=1S/C21H22N2O3/c1-14-11-15(2)16(3)20(12-14)25-13-17-7-5-6-8-18(17)21(23-24-4)19-9-10-26-22-19/h5-12H,13H2,1-4H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C21H22N2O3
Molecular Weight	350.41
AlogP	5.25
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	6.0
Polar Surface Area	56.85
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	26.0

Assay Description	Organism	Bioactivity
Fungicidal activity against Oculimacula yallundae assessed as inhibition of mycelial growth	Oculimacula yallundae	3.9 ppm
Fungicidal activity against Blumeria graminis f. sp. triticii inoculated on wheat seedlings followed by 7.8 ppm compound application 7 days after fungal inoculation assessed as wheat powdery mildew disease controlling activity relative to untreated control	Blumeria graminis f. sp. tritici	90.0 %
Fungicidal activity against Golovinomyces cichoracearum in cucumber seedlings assessed as cucumber powdery mildew disease controlling activity at 7.8 ppm applied through preventive application relative to untreated control	Golovinomyces cichoracearum	90.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2269446

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).